Beijing Airdoc Technology Co. Ltd. Class H (HK:2251)
:2251
Top Page
Beijing Airdoc Technology Co. Ltd. Class H
(2251)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$12.50
▲(0.48% Upside)
Action:ReiteratedDate:10/14/25
The overall stock score of 41 for HK:2251 reflects significant challenges, primarily driven by weak financial performance with substantial losses, declining revenue, and negative cash flow. Technical analysis indicates bearish momentum with the stock trading below key moving averages, while valuation metrics highlight unprofitability with a negative P/E ratio. The strong balance sheet provides some stability, but it is not enough to offset the broader operational and financial risks.
Positive Factors
Strong Equity Position
A high equity ratio indicates low financial leverage, providing stability and reducing financial risk, which is beneficial for long-term sustainability.
Negative Factors
Declining Revenue
A substantial drop in revenue indicates challenges in market demand or competitive positioning, which could hinder growth and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Position
A high equity ratio indicates low financial leverage, providing stability and reducing financial risk, which is beneficial for long-term sustainability.
Read all positive factors
Beijing Airdoc Technology Co. Ltd. Class H (2251) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.08B
Dividend YieldN/A
Average Volume (3M)61.23K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-32.17%
EPS Growth-1.20%
CountryHK
Employees248
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.25
Shares Outstanding103,568,016
10 Day Avg. Volume99,440
30 Day Avg. Volume61,230
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.93
Price to Sales (P/S)7.56
P/FCF Ratio-7.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)HK$251.57M
Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Air...
How the Company Makes Money
Beijing Airdoc Technology Co. Ltd. generates revenue through multiple streams, primarily from the sale of its AI-powered medical devices and software solutions to hospitals, clinics, and healthcare providers. The company's revenue model is built o...
Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
75
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.37M | 156.37M | 203.96M | 113.66M | 115.18M | 47.67M |
| Gross Profit | 97.02M | 86.68M | 125.13M | 55.85M | 70.24M | 29.09M |
| EBITDA | -175.75M | -259.70M | -113.36M | -159.64M | -126.73M | -51.97M |
| Net Income | -176.63M | -255.46M | -132.53M | -180.00M | -142.63M | -80.06M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.41B | 1.68B | 1.74B | 1.89B | 435.75M |
| Cash, Cash Equivalents and Short-Term Investments | 618.65M | 774.82M | 1.14B | 1.41B | 1.78B | 374.70M |
| Total Debt | 12.71M | 31.88M | 9.37M | 8.01M | 8.20M | 519.00K |
| Total Liabilities | 93.78M | 134.86M | 127.13M | 68.59M | 74.19M | 27.30M |
| Stockholders Equity | 1.27B | 1.27B | 1.54B | 1.67B | 1.82B | 408.21M |
Cash Flow | ||||||
| Free Cash Flow | -90.28M | -167.51M | 8.02M | -392.55M | -140.11M | -64.77M |
| Operating Cash Flow | -97.04M | -165.43M | 23.37M | -380.44M | -112.09M | -42.86M |
| Investing Cash Flow | 234.62M | -11.34M | -385.14M | -154.43M | -22.01M | 91.69M |
| Financing Cash Flow | -3.62M | -33.31M | -18.53M | -17.14M | 1.55B | 240.63M |
Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis
Negative
12.44
Price Trends
11.67
Negative
11.80
Negative
12.61
Negative
Market Momentum
-0.28
Positive
43.22
Neutral
25.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2251, the sentiment is Negative. The current price of 12.44 is above the 20-day moving average (MA) of 11.35, above the 50-day MA of 11.67, and below the 200-day MA of 12.61, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 25.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2251.
Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$1.94B | 4.06 | 7.38% | 9.29% | -3.19% | -20.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.61B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% | |
46 Neutral | HK$515.64M | -19.30 | -64.37% | 2.15% | -18.98% | -164.82% | |
45 Neutral | HK$5.46B | -110.24 | -2.28% | ― | -4.99% | 47.18% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
41 Neutral | HK$1.08B | -176.64 | -13.92% | ― | -32.17% | -1.20% |
* Healthcare Sector Average
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
10.91
-0.09
-0.82%
HK:2158
Yidu Tech, Inc.
5.12
0.15
3.02%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.75
0.37
15.55%
HK:2325
Yunkang Group Limited
0.83
-2.41
-74.38%
HK:3309
C-MER Eye Care Holdings Limited
1.31
-0.09
-6.43%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.58
49.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.